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Should we prescribe “vasodilating” beta-blockers in Marfan
syndrome to prevent aortic aneurysm and dissection?
Da li bi trebalo da propisujemo „vazodilatirajuće“ beta blokatore kod sindroma
Marfan za sprečavanje aneurizme i disekcije aorte?
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Introduction
The Marfan syndrome (MFS) was named after An-
toine Bernard-Jean Marfan (1858–1942), a French pediatri-
cian, who described the syndrome in a 5-year-old girl in
1896. 
1. There is a great deal of
 interest in medical therapy
for MFS, which protects the aorta
 and prevents or delays
surgery 
2.
MFS is a hereditary connective tissue disorder, with
the incidence of 2–3 in 10,000
  live births worldwide 
3, 4.
Approximately 15%–30% of MFS patients are due to de
novo genetic mutations, but it is mostly inherited
  as an
autosomal dominant trait, due to mutations in the fibrillin-1
gene 
5. Fibrillin-1 is the major constituent of microfibrils,
which are components of extracellular matrix, as well as of
elastic fibers 
4. Thus, in MFS connective tissues are looser
than usual, damaging the support structures of the entire
body. Elastin fibers are found throughout the body, but are
particularly abundant in the aorta, ligaments and the eye;
consequently skeletal, cardiovascular (CV) and ocular sys-
tems are among the worst affected in MFS patients 
4, 6. The
diagnosis of MFS is based on the revised Ghent crite-
ria 
3, 7, 8.
Elastic fibers are abundant in elastic arteries: up to
40% of the wall of the thoracic aorta 
9. In MFS the
amount of elastin in the aortic wall is decreased (quanti-
tative disorder), together with a loss of elastin’s normally
highly organized structure (qualitative disorder) 
10. In
systole, aorta normally expands, stretching the elastic fi-
bers and enables a portion of a stroke volume to be stored.
The aorta recoils during diastole (i.e. elastic fibers return
to their original size, bringing back the aorta to its unex-
panded diameter), so that blood continues to flow forward
from the aorta to the periphery during diastole, thus cre-
ating a nearly continuous peripheral blood flow 
9. This is
named the buffering (Windkessel) function of the aorta.
The proximal aorta provides more than half of the "buff-
ering"
 capacity of the entire arterial system, and the aorta
and some of the proximal large vessels store about 50% of
the left ventricular (LV) stroke volume during systole 
9, 11.
The Windkessel model was proposed in 1899 by
Frank 
12, 13. Buffering function allows
  blood flow to be
converted from an intermittent, pulsatile flow
 to a more
steady and laminar one, protecting sensitive end-organs
from the detrimental effects of excessive
 pressure pulsa-
tility 
11, 14.
Aortic elasticity with consequent buffering function is
very useful: it protects ascending aorta from an abrupt in-
crease of wall tension during systole, reduces LV afterload,
and improves both LV relaxation and coronary blood flow 
9.
Thus, fibrillin is the primary component of the microfibrils
that allow tissues to stretch repeatedly without weakening. In
MFS, the impaired microfibrils do not help the elastic fibers
spring back and the vulnerable, weak aorta gets stretched out
over time by the force of the blood. As it widens, the aorta
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Aortic dissection is major cause of death in Marfan
syndrome
At 30 years of age, men with MFS have an annual risk
of death of about 2%, and women have a risk of about 1%,
20–40-fold increased risk compared with the United King-
dom population
 of the same age. The mean age at death in af-
fected people is
 44 years for men and 47 years for women,
and about 70% die
  from acute CV complications, mainly
AoD 
3.
It is not a surprise, having in mind that in MFS aorta is
impaired and aorta is the largest and the strongest artery in
the body, carrying roughly 200 million liters of blood
through the body in an average lifetime 
10. A clinical
 hall-
mark and the major cause of morbidity and premature death
in MFS was and remains
 aortic root dilation and associated
aortic regurgitation,
  dissection, and rupture 
1, 6, 15, 16. Vice
versa, MFS is one of the most important risk factors for AoD
especially in the young 
10, 17, 18.
Beta-blockers are standard therapy for aortic
dissection
As a result of earlier detection, better follow-up and
both surgical and medical treatment, average life expectancy
in MFS have been increased by 30 years or more 
19. Beta-
blockers (BBs) retard the rates of aortic dilatation and AoD
in MFS 
1, 3, 15, 20. The story started in 1959, when it was an-
nouned that reserpine had prevented aortic rupture in sus-
ceptible turkeys, and continued in 1965, with successful
treatment of AoD without surgery, i.e. with antihypertensive
drugs.
 The experience with propranolol ability to slow aortic
root
 dilatation and dissection in MFS was published in 1971.
BBs are the standard treatment for MFS, since the only ran-
domized clinical trial of
 Shores et al 
2, 16, 21.
BBs have three actions, considered useful in the pre-
vention of AoD in MFS: diminishing blood pressure (BP),
heart rate (HR) and LV contractility (rate of pressure change,
dP/dt) 
1, 4, 6, 19, 22, 23. It is recommended in a nonpregnant
 pa-
tient that dosage be titrated to a resting HR of < 60
 beats per
minute 
8. If there is a contraindication for BB, verapamil has
theoretical grounds for expecting benefit in MFS, since it has
negative inotropic and chronotropic action and
 produces gen-
eralized arterial and arteriolar dilatation, with consequent BP
reduction 
3, 19. Finally, BBs have been recommended for
MFS also in the Guidelines 
24–26.
Antiarhythmic and antifibrillatory effect of BBs may
also be useful in MFS 
21. Tachyarrhythmias may result from
mitral valve prolapse, which is very common in MFS (60%–
80%) 
4, 21. Even in the absence of regurgitant lesions,
 LV di-
lation occurs commonly in patients with MFS, and it gener-
ates arrhythmias 
27. The incidence of ventricular
 arrhythmias
is significant with a mortality rate from presumed
 arrhyth-
mogenic death of 4%, which might exceed the rate of aortic
rupture as Yetman et al. 
27 suggested.
From a pragmatic standpoint, additional benefit may be
expected from BBs which act longer (once-a-day formula),
because they may be less dangerous if the dose is omitted.
Namely, BBs are a typical example for the drugs capable of
inducing rebound phenomenon 
28. There is a case report of a
patient who got AoD following the BBs dose omission and
consequent BBs rebound effect 
29. It is not surprising, be-
cause sympathetic surge has been known as the important
physiopathologic mechanism for AoD since it augments the
pressures in aorta and both the number and the intensity of
strokes into the aortic wall 
30.
On the other hand, it is unacceptable that MFS patients
with increased aortic diameters are given BBs treatment
based on
 one unblinded trial, published over 10 years ago
and two retrospective trials in children 
31, 32.
However, pending the outcome of randomized con-
trolled trials
 and based on the limited published data, Wil-
liams et al.
 3 suggest that BBs
 should remain the first-line
treatment of aortic dilatation in MFS. In a small (17 patients)
randomized double-blind trial, the ACE inhibitor perindopril
reduced aortic stiffness and even aortic root diameter com-
pared to placebo when given to adult MFS patients in addi-
tion to BB treatment for 24 weeks 
33.
To our knowledge, there is no more randomized, dou-
ble-blind clinical trials with other drugs published, but a
couple of them (mostly with angiotensin receptor blockers)
are ongoing. One interesting trial compares effects of losar-
tan vs. nebivolol vs. the association of both on the progres-
sion of aortic root dilation in MFS 
34.
 Losartan antagonizes
TGF-β, which has been shown to prevent aortic elastic fibre
degeneration. Nebivolol exerts antistiffness effects 
34, and
aortic stiffness is increased and relates to aortic disease pro-
gression in MFS 
35.
BBs in uncomplicated arterial hypertension: not the
first-line antihypertensives anymore
BBs have been used in arterial hypertension (AHT) for
decades, but their role in uncomplicated AHT was chal-
lenged for the first time in 1998 
36. “The time has come to
admit that BBs should no longer be considered appropriate
for the first-line therapy of uncomplicated AHT” 
37. Com-
pared with other antihypertensives, BBs are less effective for
preventing CV events in patients with uncomplicated
AHT 
38, 39. Moreover, two recent meta-analyses showed that
despite reducing brachial BP, BBs was not effective in re-
ducing CV events when compared with either placebo or
other antihypertensive agents 
40–42. BBs increases
 peripheral
vascular resistance, which in turn may increase central
 aortic
pressure and wall stress 
3, 22, 43.
BBs lower central aortic BP to a lesser degree even when
BP measured by sphygmomanometry is reduced substantially.
Given the strong relationship between central aortic BP and
target organ damage, the effectiveness of BBs may be overes-
timated in practice on the basis of conventional BP measure-
ments alone 
38. Despite a "beneficial"
 effect on the brachial BP,
which is surrogate end point, BBs
 failed to favorably affect the
clinical end point, i.e., coronary artery disease and
 CV mortal-
ity and all-cause mortality 
36. The increase in the augmentation
index reported after BBs results in increased central systolic
BP in hypertensive patients. Thus, BBs could have a deleteri-
ous effect on LV-aortic coupling, LV afterload, LV hypertro-
phy, and, ultimately, the risk of CV events 
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rate is an obvious mechanism for the higher central BP with
BB–based therapy noted in the Conduit Artery Function
Evaluation (CAFE) study 
45.
BBs’ side effects are also important, including: pre-
cipitation of diabetes mellitus, little effect on regression of
LV hypertrophy, likely failure to improve endothelial func-
tion, weight gain and decrease in exercise endurance 
45, 46.
Thus, National Institute for Clinical Excellence downgraded
BBs from the first-line drug choice for uncomplicated AHT.
In head-to-head trials, BBs were usually less effective than a
comparator drug at reducing major CV events, in particular
stroke. Atenolol was the BBs used in most of these studies
and, in the absence of substantial data on other agents, it is
unclear whether this conclusion applies to all BBs. BBs are
not a preferred initial therapy for AHT. However, BBs may
be considered in younger people, particularly: those with an
intolerance or contraindication to angiotensin converting en-
zyme (ACE) inhibitors and angiotensin receptor blockers, or
women of child-bearing potential, or people with evidence of
increased sympathetic drive 
47.
On the contrary, European Society of Hypertension and
of the European Society of Cardiology recommended: “BBs
may still be considered an option for initial and subsequent
antihypertensive treatment strategies. …they should not be
preferred, however, in hypertensives with multiple metabolic
risk factors including the metabolic syndrome…” 
48. Contem-
porary titles in leading medical journals give us also picture
about current status of BBs: “Beta-blockers in hypertension:
adding insult to injury”
 45. “Hypertension in the elderly: a
compelling contraindication for β-blockers?” 
49. “Beta-
blockers in hypertension-the emperor has no clothes”
 37.
Importance of central aortic (and carotid) blood
pressure
Although the differences between central (aortic and ca-
rotid) and peripheral BP have been known for decades, the con-
sequences of decision-making based on peripheral rather than
central BP have only recently been recognized
 50.  Although
brachial measurement may accurately determine diastolic BP, it
does not accurately reflect systolic BP. This is mainly attributed
to the fact that BP waveform is distorted as it travels outward
from the heart due to the presence of wave reflections from the
peripheral arteries 
51. Brachial systolic and pulse pressures tend
to overestimate central
 systolic and pulse pressures, especially
in younger subjects who have more
 pronounced amplification,
but also in older people, especially
 with tachycardia, exercise,
use of vasoactive agents, or in
 those with systolic heart fail-
ure 
52, 53. The superior prognostic utility of central compared
with brachial BP was demonstrated in an unselected geriatric
population
54 in patients with coronary artery disease,
 in patients
with end-stage renal
 failure, etc 
52. Moreover, young African-
American men have greater central
  BP, despite comparable
brachial BP compared with young white
 men 
14.
Central (aortic and carotid) pressures are pathophysi-
ologically more relevant than peripheral pressures for the
pathogenesis
 of CV disease. It is aortic systolic BP
 that the
LV encounters during systole (afterload),
 and the aortic BP
during diastole is a determinant of
 coronary perfusion 
14, 51, 52.
More and more clinical studies suggest that central BP may
provide additional information regarding CV risk beyond pe-
ripheral BP 
50–52, 55–58. Recent findings suggest that the pulsa-
tile component of BP (when represented by central pulse
pressures or central pulsatility) is one of the most important
factors determining event-free survival, because it acceler-
ates atherosclerosis and leads to plaque rupture in coronary
arteries 
50. Recent large-scale trials have shown that
 central
hemodynamics may provide a worthwhile treatment target 
52.
ACE inhibitors, angiotensin receptor blocketrs and dihydro-
pyridine calcium blockers diminish central BP 
59.
Effects on central pressures may not be evident by pres-
sure
  measurements in the periphery, because the reflected
wave is
 added to a different part of the central waveform. This
may
 explain why drugs with similar reduction in peripheral
pressures
 have a differential impact on CV outcomes 
52. Im-
portant multicenter trials
  gave rise to the hypothesis that
blockers of the renin–angiotensin system, may
 reduce CV out-
comes beyond (peripheral) BP control, perhaps by decreasing
also central BP and protecting from
  subclinical organ dam-
age 
52. Besides, there is compelling evidence regarding the det-
rimental effect of BBs (mainly atenolol) on central BP 
59.
However, the prognostic role of central as opposed to periph-
eral BP needs to be further confirmed in more large-scale ob-
servational and interventional studies 
48.
Blood pressure in the aorta (central blood pressure)
is important for aortic dissection genesis
The strong argument for the abovementioned statement
comes from the fact that AHT is recognized as the most im-
portant cause of AoD 
24. Central pulse pressure is a major
determinant of ascending aorta dilation in MFS 
60. Over time,
and presumably as a consequence of central BP and waves
acting on the stiff aortic wall, the aortic
 diameter enlarges,
which increases the risk of AoD 
3. In patients with
 malignant
AHT, reducing BP to normal but
 not reducing the rate of
change in the central arterial pressure
 with respect to time
(dP/dt) did not prevent AoD
  but apparently increased its
risk 
21, 61. The theoretical
 reason suggested for the beneficial
effect of BBs
 on Marfan aortas was the decrease in the rate
of change in central
 arterial pressure (dP/dt)
 3. Central pulse
pressure, which takes into account wave reflections and aor-
tic stiffness, is a better determinant of ascending aorta di-
ameter than brachial pulse pressures in MFS patients, inde-
pendently of age and body surface area 
6.
Vasodilating BBs decrease also central (aortic) blood
pressure and they are recommended in arterial
hypertension
Atenolol may even increase central BP 
59, 62. Hemody-
namic effects of vasodilating BBs clearly differ. Carvedilol
and labetalol appear to cause vasodilation through α-1 re-
ceptor blockade; nebivolol induces endothelium-dependent
vasodilation by stimulating nitric oxide bioactivity. Their fa-
vorable hemodynamic profile includes reduction of pulmo-
nary vascular resistance, while maintaining or improving
cardiac output, stroke volume, and LV function, whereas
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tance and reduce cardiac output and LV function. Compared
with conventional BBs, vasodilating BBs have beneficial
hemodynamic effects including decreased pressure wave re-
flection from the periphery, leading to decreases in central
aortic BP 
42, 63–65. Nebivolol improves endothelial function,
leading to a reduction in arterial stiffness, with beneficial
hemodynamic effects including reductions in central aortic
BP 
42, 62, 63. Central hemodynamic at rest and during exercise
were recorded 1 h and 2 h after carvedilol tablet and the re-
sults indicated a combined BBs and vasodilating effect 
66.
Besides, vasodilating BBs have been preferred in AHT
due to metabolic profile 
48, 67, 68. Namely, non-vasodilating
BBs have higher potential to elevate blood glucose and cho-
lesterol level. The risk which should not be neglected, as
Messerli et al. 
69 warn: in uncomplicated AHT, diuretics and
BBs should no longer be considered for the first-line treat-
ment. The trade-off of lowering BP at the expense of in-
creasing risk for diabetes mellitus by up to 10% yearly is not
acceptable. The risk for diabetes mellitus is greater with
atenolol, in the elderly, and in studies in which BBs were
less efficacious antihypertensive agents and increased expo-
nentially with longer duration on BBs 
67. BBs have been
shown to inhibit pancreatic insulin secretion (via β-2 recep-
tors), worsen insulin resistance, cause weight gain, diminish
peripheral blood flow, and lead to increased glycogenolysis
(by unopposed α-2 action), all of which are implicated in ad-
verse glycemic control. This is not a class effect, and BBs
with intrinsic sympathomimetic effects, β-1 selective block-
ers with β-2 agonist properties, and newer noncardioselective
BBs with vasodilating properties (such as carvedilol) have
minimal effects on glycemic control 
67.
Metabolic studies evaluated the effects of vasodilating
BBs, such as dilevalol, carvedilol and celiprolol, on insulin
sensitivity and the atherogenic risk factors. None of them de-
creased insulin sensitivity, as has been described for the BBs
with and without β-1 selectivity. This supports the idea that
peripheral vascular resistance and peripheral blood flow play
a central role in mediating the metabolic side effects of the
BBs, as the vasodilating action (either via β-2 stimulation or
α-1 blockade) seems to more than offset the detrimental ef-
fects of the blockade of β (or β-1) receptors 
70. Indeed  long-
term CV outcome in AHT treated with carvedilol or nebivo-
lol is still not known 
65.
Vasodilating BBs decrease also central (aortic) blood
pressure: should not they also be considered in
Marfan syndrome to prevent aortic aneurysm and
aortic dissection?
Our idea is: if BBs with better impact upon central BP
are preferred in AHT, why should not they also be preferred
in MFS to prevent aortic aneurysm and AoD? Namely, cen-
tral BP means BP in the aorta, where also the prevention tar-
get in MFS is. If vasodilating BBs have the advantage in
AHT due (among others) to better performances at this par-
ticular site (aorta), they may be also better suited for MFS as
well. Metabolic profile of vasodilating BBs may be addi-
tional argument to consider them as the first line choice for
patients with MFS, because prevention is expected to be
prolonged, usually life-long.
A word of caution is needed, because neither we have a
definite proof from large trials that central BP is clearly su-
perior prognosticator, nor that vasodilating BBs improve
outcomes in terms of survival and freedom from myocardial
infarctions and strokes better than classical BBs.
Finally, there are two premises, i.e. sentences from the
literature. The first is: central pulse pressure is a major de-
terminant of ascending aorta dilation in MFS 
6. The second
follows: compared with conventional BBs, vasodilating BBs
have beneficial hemodynamic effects including decreased
pressure wave reflection from the periphery, leading to de-
creases in central aortic BP 
63. The conclusion is obvious
from the premises: vasodilating BBs may have the advantage
in preventing aortic complications in MFS. Indeed, to obtain
a valid conclusion, promises should be checked.
A PubMed search for terms: “central blood pressure
Marfan” retrieved 11 papers, and for “central blood pressure
Marfan beta blocker” only two (30
st March. 2010). None of
them had evaluation of the potential role of vasodilatatory
BBs in the prevention of aortic aneurysm and AoD in MFS.
Conclusion
In the recent guidelines for arterial hypertension BBs
(in the absence of compelling indications) have been re-
moved from the first-line antihypertensive therapy – in part
due to insufficient efficacy in decreasing central BP. It is
probable that central (aortic) BP reduction is central for the
prevention of aortic dilatation, AoD and rupture in MFS.
Thus, the same inefficacy of classic BBs to decrease central
BP may be the reason to consider them less effective in the
prevention of aortic aneurysm and AoD in MFS. On the
other hand, vasodilating BBs might have larger efficacy in
decreasing central BP and thus in delaying aortic complica-
tions in MFS. Metabolic profile of vasodilating BBs should
be another argument to use them in MFS, because a pro-
longed application is expected. This issue deserves more at-
tention, in order to better prevent catastrophic diseases (aor-
tic aneurysm and AoD) in MFS. Indeed, randomized con-
trolled trials as well as large registries’ data are needed to
obtain a more precise answer.
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